<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9B4CA5C7-E2C8-4736-BF8E-46D08D8D741E"><gtr:id>9B4CA5C7-E2C8-4736-BF8E-46D08D8D741E</gtr:id><gtr:name>Center for Perinatal Studies, Rosarino (CREP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9B4CA5C7-E2C8-4736-BF8E-46D08D8D741E"><gtr:id>9B4CA5C7-E2C8-4736-BF8E-46D08D8D741E</gtr:id><gtr:name>Center for Perinatal Studies, Rosarino (CREP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8F4191DC-98B5-4C58-89B3-8C4C67CBBFC2"><gtr:id>8F4191DC-98B5-4C58-89B3-8C4C67CBBFC2</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Brocklehurst</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/79DCD55E-311C-4A1B-90FC-1AA206739221"><gtr:id>79DCD55E-311C-4A1B-90FC-1AA206739221</gtr:id><gtr:firstName>Khalid</gtr:firstName><gtr:surname>Haque</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/21F65A5E-97A4-4F40-9BF3-888A71239FEC"><gtr:id>21F65A5E-97A4-4F40-9BF3-888A71239FEC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Leslie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B3416C25-79BB-40B9-8A12-1679A5C5149A"><gtr:id>B3416C25-79BB-40B9-8A12-1679A5C5149A</gtr:id><gtr:firstName>Benjamin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Stenson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6A382DE4-9CDC-49BB-BF5F-2BED79BD04A0"><gtr:id>6A382DE4-9CDC-49BB-BF5F-2BED79BD04A0</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Odita</gtr:otherNames><gtr:surname>Tarnow-Mordi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9900825"><gtr:id>CDB71544-FB0C-42B6-9A5C-EF7CA28BAB60</gtr:id><gtr:title>International Neonatal Immunotherapy Study (INIS)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9900825</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This proposal is for a placebo controlled, pragmatic, multicentre randomised controlled trial, to investigate whether non-specific intravenous immunoglobulin therapy reduces mortality and morbidity of infants receiving antibiotics for a neonatal sepsis.

Neonatal sepsis has a mortality rate of about 8% and evidence continues to emerge that neonatal sepsis is a major risk factor for subsequent chronic lung-disease and major neurodevelopmental delay. Current Conventional management of neonatal sepsis relies on antibiotic therapy, however, in recent years a variety of other agents have been suggested which can be used in addition to antibiotics to improve the outcome for these babies. Of these the most promising to date appears to be the use of non-specific immunoglobulin. In a systematic review of small randomised controlled trials this appeared to half the death rate ( although this was imprecisely estimated). There have been no reports of long-term follow up of these trial populations.

This proposed trial will randomise 5000 neonates with a diagnosis of presumed neonatal sepsis to receive either intravenous immunoglobulin or placebo. The immunoglobulin will be given in a dose of 500mg (10ml) per kg and repeated after 48 hours. The primary outcome measures are death or major disability at age 2 years. Secondary outcomes include chronic lung disease and major cerebral abnormalities before hospital discharge. An intention-to- treat analysis will be performed and predefined subgroup analysis will be based on the clusters of clinical signs and laboratory data which led to the presumptive diagnosis of sepsis leading to trial entry.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3105176</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>NHMRC Clinical Trials Centre (CTC)</gtr:department><gtr:description>The INIS Study Collaborative Group</gtr:description><gtr:id>AB83A084-F6F6-470B-A4BF-1CCB5F2F546E</gtr:id><gtr:impact>The INIS Study protocol
Treatment of Neonatal Sepsis with Intravenous Immune Globulin</gtr:impact><gtr:partnerContribution>Professor William Tarnow-Mordi is a co-applicant on the MRC grant and is based in the University of Sydney. He and his team contributed to the development of the protocol and study documentation. Since recruitment began they have co-ordinated recruitment in 14 Australian hospitals and 7 in New Zealand. The Clincial Trials Centre in the University of Sydney has maintained the INIS study database, dealt with all data queries, reported all adverse events. The database has been regularly transmitted to Oxford for inclusion in the overall study data. The CTC have been regularly involved in the progress of the trial and its development since 2000.Professor Brian Darlow and his team in the Neonatology Department of Christchurch Hospital, New Zealand have enrolled a substantial number of babies in the INIS Study, collected the relevant data up until discharge from hospital, followed-up all babies until 2 years of age and carried out a Bayley Paediatric Assessment on these children.Centro Rosarino de Estudios de Perinatales (CREP) co-ordinated the participation of 14 hospitals across Argentina. CREP used a in-house translator to translate the INIS protocol and all INIS documentation for use in Argentina. CREP were responsible for resolving all data queries, providing translations of any free text, arranging for follow-up of all babies at two years of age and forwarding all clean data to Oxford for data entry.</gtr:partnerContribution><gtr:piContribution>The INIS Co-ordianting Centre at NPEU Clincial Trials Unit has been responsible for developing the study, securing MRC funding, establishing the collaborative group and taking overall repsonsibility for recruitment monitoring, data entry, cleaning and analysis. Reporting to funders, the ethics committee and the MHRA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Center for Perinatal Studies, Rosarino (CREP)</gtr:collaboratingOrganisation><gtr:country>Argentina, Argentine Republic</gtr:country><gtr:description>The INIS Study Collaborative Group</gtr:description><gtr:id>2E20CAA2-0C4F-408D-892D-D0CA05D9506E</gtr:id><gtr:impact>The INIS Study protocol
Treatment of Neonatal Sepsis with Intravenous Immune Globulin</gtr:impact><gtr:partnerContribution>Professor William Tarnow-Mordi is a co-applicant on the MRC grant and is based in the University of Sydney. He and his team contributed to the development of the protocol and study documentation. Since recruitment began they have co-ordinated recruitment in 14 Australian hospitals and 7 in New Zealand. The Clincial Trials Centre in the University of Sydney has maintained the INIS study database, dealt with all data queries, reported all adverse events. The database has been regularly transmitted to Oxford for inclusion in the overall study data. The CTC have been regularly involved in the progress of the trial and its development since 2000.Professor Brian Darlow and his team in the Neonatology Department of Christchurch Hospital, New Zealand have enrolled a substantial number of babies in the INIS Study, collected the relevant data up until discharge from hospital, followed-up all babies until 2 years of age and carried out a Bayley Paediatric Assessment on these children.Centro Rosarino de Estudios de Perinatales (CREP) co-ordinated the participation of 14 hospitals across Argentina. CREP used a in-house translator to translate the INIS protocol and all INIS documentation for use in Argentina. CREP were responsible for resolving all data queries, providing translations of any free text, arranging for follow-up of all babies at two years of age and forwarding all clean data to Oxford for data entry.</gtr:partnerContribution><gtr:piContribution>The INIS Co-ordianting Centre at NPEU Clincial Trials Unit has been responsible for developing the study, securing MRC funding, establishing the collaborative group and taking overall repsonsibility for recruitment monitoring, data entry, cleaning and analysis. Reporting to funders, the ethics committee and the MHRA</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Christchurch Hospital</gtr:department><gtr:description>The INIS Study Collaborative Group</gtr:description><gtr:id>C927B080-13B6-4BE9-B85C-9CDA4719E88B</gtr:id><gtr:impact>The INIS Study protocol
Treatment of Neonatal Sepsis with Intravenous Immune Globulin</gtr:impact><gtr:partnerContribution>Professor William Tarnow-Mordi is a co-applicant on the MRC grant and is based in the University of Sydney. He and his team contributed to the development of the protocol and study documentation. Since recruitment began they have co-ordinated recruitment in 14 Australian hospitals and 7 in New Zealand. The Clincial Trials Centre in the University of Sydney has maintained the INIS study database, dealt with all data queries, reported all adverse events. The database has been regularly transmitted to Oxford for inclusion in the overall study data. The CTC have been regularly involved in the progress of the trial and its development since 2000.Professor Brian Darlow and his team in the Neonatology Department of Christchurch Hospital, New Zealand have enrolled a substantial number of babies in the INIS Study, collected the relevant data up until discharge from hospital, followed-up all babies until 2 years of age and carried out a Bayley Paediatric Assessment on these children.Centro Rosarino de Estudios de Perinatales (CREP) co-ordinated the participation of 14 hospitals across Argentina. CREP used a in-house translator to translate the INIS protocol and all INIS documentation for use in Argentina. CREP were responsible for resolving all data queries, providing translations of any free text, arranging for follow-up of all babies at two years of age and forwarding all clean data to Oxford for data entry.</gtr:partnerContribution><gtr:piContribution>The INIS Co-ordianting Centre at NPEU Clincial Trials Unit has been responsible for developing the study, securing MRC funding, establishing the collaborative group and taking overall repsonsibility for recruitment monitoring, data entry, cleaning and analysis. Reporting to funders, the ethics committee and the MHRA</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0D5D174-5716-4B0C-B698-3E4F0650B3C8"><gtr:id>F0D5D174-5716-4B0C-B698-3E4F0650B3C8</gtr:id><gtr:title>The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial.</gtr:title><gtr:parentPublicationTitle>BMC pregnancy and childbirth</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3fa276aec99a03cb7ba34f607e498e0"><gtr:id>b3fa276aec99a03cb7ba34f607e498e0</gtr:id><gtr:otherNames>INIS Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-2393</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0FDE9C40-5537-4B85-942D-B4E258D42635"><gtr:id>0FDE9C40-5537-4B85-942D-B4E258D42635</gtr:id><gtr:title>Treatment of neonatal sepsis with intravenous immune globulin.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57d07175fde031608488314dcefaacf9"><gtr:id>57d07175fde031608488314dcefaacf9</gtr:id><gtr:otherNames>INIS Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC861D4F-E353-43E3-97E6-79D567C7AF04"><gtr:id>AC861D4F-E353-43E3-97E6-79D567C7AF04</gtr:id><gtr:title>Performance of the Parent Report of Children's Abilities-Revised (PARCA-R) versus the Bayley Scales of Infant Development III.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689f7e3ca9df163485dd34a210a5923c"><gtr:id>689f7e3ca9df163485dd34a210a5923c</gtr:id><gtr:otherNames>Martin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E0DFA5C-AD11-4C6F-A0A6-44F211992E2D"><gtr:id>0E0DFA5C-AD11-4C6F-A0A6-44F211992E2D</gtr:id><gtr:title>Identification of infants with major cognitive delay using parental report.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689f7e3ca9df163485dd34a210a5923c"><gtr:id>689f7e3ca9df163485dd34a210a5923c</gtr:id><gtr:otherNames>Martin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9900825</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>